Alpine Immune Sciences (NASDAQ:ALPN) Announces Quarterly Earnings Results, Misses Estimates by $0.06 EPS
Alpine Immune Sciences (NASDAQ:ALPN – Get Rating) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.06), Fidelity Earnings reports. Alpine Immune Sciences had a negative return on equity of 59.07% and a negative net margin of 214.70%.
Alpine Immune Sciences stock opened at $7.55 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.75 and a quick ratio of 2.75. The company’s 50-day moving average is $8.56 and its 200 day moving average is $10.01. Alpine Immune Sciences has a 1-year low of $6.00 and a 1-year high of $15.14.
Hedge funds have recently modified their holdings of the business. Citigroup Inc. grew its stake in Alpine Immune Sciences by 184.0% in the 4th quarter. Citigroup Inc. now owns 3,766 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 2,440 shares in the last quarter. Bank of America Corp DE grew its stake in Alpine Immune Sciences by 46.7% in the 4th quarter. Bank of America Corp DE now owns 4,944 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 1,573 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Alpine Immune Sciences by 62.6% in the 4th quarter. JPMorgan Chase & Co. now owns 7,250 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 2,790 shares in the last quarter. Parametric Portfolio Associates LLC bought a new position in shares of Alpine Immune Sciences during the fourth quarter valued at approximately $151,000. Finally, Goldman Sachs Group Inc. bought a new position in shares of Alpine Immune Sciences during the fourth quarter valued at approximately $185,000. Institutional investors and hedge funds own 77.00% of the company’s stock.
Several analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $21.00 price target on shares of Alpine Immune Sciences in a research note on Friday. Zacks Investment Research lowered shares of Alpine Immune Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, March 22nd. Finally, Oppenheimer reduced their price objective on shares of Alpine Immune Sciences from $19.00 to $17.00 in a research report on Monday, March 7th.
Alpine Immune Sciences Company Profile (Get Rating)
Alpine Immune Sciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases.
- Get a free copy of the StockNews.com research report on Alpine Immune Sciences (ALPN)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded